Finnrick, an independent testing programme, publishes 17 assays for Retalux: 16 met its Purity focus threshold (at least 99.5% purity, no more than 35% dosage deviation) and 1 did not. Most recent assay 5 Aug 2026.
Retalux listed by Finnrick as "Trading", has no storefront on record — Finnrick lists only a messaging or social contact. Source: Finnrick, https://www.finnrick.com/vendors/retalux.
Listed in the Finnrick vendor directory. Not yet tested.
Retalux is listed as active. Tracked by Finnrick. No test data available yet.
No independent third-party assay is on file for Retalux, and we have not yet compiled a profile of its own website. An untested vendor has not failed a test — this is an absence of evidence, not evidence against it.
| Product | Assays | Result |
|---|---|---|
| Retatrutide | 8 | 7 passed, 1 failed |
| Tirzepatide | 5 | 5 passed, 0 failed |
| SS-31 | 4 | 4 passed, 0 failed |
Source: Finnrick, as published 2026-08-09. Pass and fail are Finnrick's classification against its own threshold, not ours.
| Status | Active |
|---|---|
| Vendor type | Research-use supplier |
Retalux is listed as active and we hold 17 Finnrick assays (16 passing, 1 failing its purity threshold). That is evidence about the batches that were tested or published, not a guarantee about the vial you receive.
Yes. Finnrick, an independent testing programme, publishes 17 assays for Retalux: 16 met its Purity focus threshold (at least 99.5% purity, no more than 35% dosage deviation) and 1 did not. Most recent assay 5 Aug 2026.
Popular peptides: Semaglutide, Tirzepatide, Retatrutide, BPC-157, CJC-1295, Ipamorelin.
Other reviewed vendors: RetaOne Labs Peptides Review, Rethel Jinan New Energy Technology Peptides Review, Revico Labs Peptides Review.